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nc-nd/4.0/).A recent study by Xie et al. [1] suggests that metabolic adjustments in
erythrocytes affect progressionofhypertensivekidneydiseasebyregulating
tissue oxygen delivery. The study provides novel mechanisms in the path-
ogenesis of renal disease and potential treatment targets. Given the sub-
stantial energy demand of tubular solute reabsorption, the kidneys are
highly metabolically active organs consuming around 7% of the oxygen
taken up by the body.While comprising nomore than 2%of bodymass, the
kidneys receive approximately 22% of resting cardiac output. Despite this
apparent luxury perfusion - oxygen extraction is lower than in many other
organs - kidneys show a steep oxygen gradient with decreasing oxygen
partial pressure from cortical towards medullary portions. Indeed, local
tissue oxygen partial pressures may be as low as 10 mmHg in the renal
medulla [2]. In contrast, other vital organs, like the heart, the liver and the
brain, operate at tissue oxygen partial pressures above 30 mmHg [3].
Further reductions in renal oxygen tension can cause acute renal failure.
In fact, highly trainedandhealthymountaineersmay experience reductions
in kidney function and albuminuria, the so-called high altitude renal syn-
drome (HARS), at altitudes above 7000 m [2]. Renal tubular cells,
well-endowedwithenergy consumingNaþ/Kþpumps,areprone tohypoxic
damage. Moreover, hypoxia promotes transition from acute to chronic
kidneydisease [4].Renal tubular cells respond tosustainedoxygenshortage
with epithelial-mesenchymal transdifferentiation into myofibroblasts [5].
Hypoxia also activates fibroblasts and may change extracellular matrix
characteristics. The resulting renal tubulointerstitial fibrosis, a hallmark of
chronic kidney disease, drives further renal function loss including reduced
erythropoietin release with subsequent anemia [6]. Renal microvascular
rarefication and glomerular sclerosis foster renal hypoxia with advancing
age [7]. Avoiding renal tissue hypoxia could conceivably ameliorate
fibrogenesis and slow the decline in kidney function.
Theoretically, oxygen consumption and oxygen supply could be
tweaked to improve renal oxygenation. In fact, mechanisms regulation
renal oxygen consumption have been an important scientific focus in
recent years. For example, worsened renal energy efficiency through
mitochondrial uncoupling has been observed in diabetic kidney disease
[8]. Conversely, more efficient mitochondria convey renal hypoxia toler-
ance in animals [9]. In many organs, increased perfusion is the prime
mechanism matching oxygen supply to increased oxygen demand. In the
kidney, however, increased perfusion results in concomitant increases in
glomerular solute filtration. Filtered solutes have to be reclaimed through020
vier B.V. This is an open access arenergy-dependent tubular reabsorption such that oxygen demand in-
creases with increasing perfusion. Alternatively, the amount of oxygen
released at a given perfusion rate could increase. A recent study in
mountaineers suggested that sphingosine-1-phosphate signaling in eryth-
rocytes protects against tissue hypoxia at high altitude by improving ox-
ygen release [10].
Xie et al. [1] generated mice with erythrocyte lineage-specific ablation
of the gene encoding sphingosine kinase 1, which produces
sphingosine-1-phosphate. Chronic angiotensin II infusion elicited a more
pronounced increase in blood pressure, renal damage, and renal hypoxia in
mice with erythrocyte lineage-specific sphingosine kinase 1 knockout
compared towildtypemice. The differential response was not explained by
differences in erythropoiesis secondary to renal disease. In knockout ani-
mals, erythrocyte sphingosine-1-phosphate concentrations were low and
did not respond to angiotensin II infusion. In contrast, erythrocyte
sphingosine-1-phosphate concentrations were much higher in wildtype
animals and increased further with angiotensin II infusion likely through
sphingosine kinase 1 induction. Together, these observations suggest that
sphingosine-1-phosphate generation in erythrocytes protects the kidney
from hypoxia associated damage elicited through angiotensin II.
Next, Xie et al. [1] identified metabolites and metabolic pathways in
erythrocytes differentially affected by angiotensin II. The glycolysis
pathway was significantly affected in knockout mice with angiotensin II
infusion compared to wildtype mice. Among glycolytic intermediates, 2,
3-bisphosphoglycerate was particularly strongly induced by angiotensin
II in wildtype mice. The response was obliterated in knockout mice. Over
decades, physiology professors have touted that 2,3-bisphosphoglycerate
modulates hemoglobin oxygen binding such that oxygen delivery in pe-
ripheral tissues is improved. Here is a useful application. Detailed meta-
bolic analyses utilizing labeledmetabolites among other tools showed that
angiotensin II induces bisphosphoglycerate mutase, the enzyme gener-
ating 2,3-bisphosphoglycerate, in wildtype but not in knockout mice.
AMP-activated protein kinase and protein phosphatase 2A appear to be
involved. Indeed, pharmacological AMP-activated protein kinase activa-
tion and protein phosphatase 2A inhibition rescued the chronic kidney
disease phenotype in knockout animals. Clinicians may find it intriguing
that metformin also activates AMP-activated protein kinase. Finally, pre-
liminary studies in erythrocytes obtained from patients with chronic kid-
ney disease reproduced some of the findings in mice.ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
Invited Commentary International Journal of Cardiology Hypertension 7 (2020) 100049Overall, the study focusses our attention on the interaction between
metabolic programming and hypoxia on kidney disease progression. The
idea that the sphingosine-1-phosphate mechanism could be engaged
through hypoxia acclimatization [10] is intriguing.
Sphingosine-1-phosphate may also convey endothelial protection during
intermittent hypoxia [11]. Yet, systemic intermittent hypoxia has also
been implicated in the progression of chronic kidney disease in patients
with chronic obstructive pulmonary disease [12]. We dare to speculate
that while too much hypoxia may damage the kidney, individualized
hypoxia training could have utility in ameliorating kidney disease.
Metabolic programingmayalso affect target organ tolerance tohypoxia.
A shift towards fructose metabolism is a highly conserved evolutionary
mammalian mechanism protecting tissues against hypoxia among other
stresses [13]. Nakedmole rats survive prolonged anoxia by switching their
metabolism to fructose based energy generation [14]. In a rodentmodel for
kidney transplantation, fructose-1,6-diphosphate increased the viability of
kidney grafts during cold ischemia [15]. Furthermore, in patients under-
going cardiac bypass surgery, intravenous fructose-1-6-diphosphate infu-
sion was associated with reduced likelihood of experiencing postoperative
myocardial infarction and better cardiac function [16]. Finally, hypoxia
may affect tissue regeneration. A functioning hypoxia –
hypoxia-inducible-factor – von-Hipple-Lindau-gene axis is mandatory for
the differentiation of nephron progenitor cells [17]. The regenerative ca-
pacity of many adult tissues including the kidneys is limited. The phe-
nomenonmay be explained inpart byoxidative stress-induced activation of
the DNA damage response resulting in cell cycle arrest [18]. In mice,
myocardial regeneration can be rescued by severe sustained hypoxia [19].
Overall, we suggest that recognition of the mechanisms orchestrating the
interaction between hypoxia and the kidney may pave the way to novel
therapies ameliorating kidney disease. The sphingosine-1-phosphate
mechanism in erythrocytes is not the only pathway worth pursuing.
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